Angiogec potential of PAF receptor ligands in irradiated tumors

• Grant number: 17/23041-5
• Support Opportunities: Scholarships in Brazil - Master
• Effective date (Start): March 01, 2018
• Effective date (End): October 31, 2019
• Field of knowledge: Biological Sciences - Immunology - Applied Immunology
• Acordo de Cooperação: Coordination of Improvement of Higher Education Personnel (CAPES)
• Principal Investigator: Sônia Jancar
• Grantee: Ana Carolina Chiacetti Rodrigues
• Host Institution: Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brazil

Abstract

Recent evidence suggests the participation of the lipid mediator "Platelet Activating Factor" (PAF) in tumor growth and resistance to chemo-radiotherapy. PAF acts through a G protein-coupled receptor (PAFR), expressed on tumor cells and also on the tumoral infiltrate cells. It has been shown that irradiation leads to the generation of a series of oxidized phospholipids that act as PAFR agonists in the tumor microenvironment. The activation of PAFR induces survival and proliferation of tumor cells. Preliminary results from our group showed that subcutaneous injection of tumor cells expressing the PAF receptor (PAFR +) generate significantly larger and more vascularized tumors than negative PAFR tumors, suggesting the participation of PAF as a pro-angiogenic factor. Thus, understanding the signals that regulate tumor angiogenesis is fundamental for the development of new therapeutic alternatives. Thus, our work hypothesis aims to evaluate whether ligands of PAFR produced in the irradiated tumor microenvironment contribute to tumor angiogenesis, amplifying the phenomenon of tumor repopulation after irradiation. This hypothesis will be investigated in an innovative model of tumor spheroid (3D) using human tumor cells. (AU)

Academic Publications

(References retrieved automatically from State of São Paulo Research Institutions)

RODRIGUES, Ana Carolina Chiacetti. Angiogenic potential of PAF receptor ligands in irradiated tumors.. 2019. Master's Dissertation - Universidade de São Paulo (USP). Instituto de Ciências Biomédicas (ICB/SDI) São Paulo.